Navigation Links
Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Date:10/23/2007

nding dose study, all possibly-related adverse events were mild in severity and resolved spontaneously.

The Company expects to initiate a Phase 2 clinical trial of AT2220 for Pompe disease in early 2008. "We are pleased to be able to advance this program forward in development and explore the potential for AT2220 as a new therapeutic option for people living with Pompe disease," said John F. Crowley, President and CEO of Amicus Therapeutics.

About Pompe Disease

Pompe disease affects an estimated 5,000-10,000 patients worldwide and is clinically heterogeneous in the age of onset, the extent of organ involvement, and the rate of progression. The early onset form of the disease is the most severe, progresses most rapidly, and is characterized by musculoskeletal, pulmonary, gastrointestinal, and cardiac symptoms that usually lead to death from cardio-respiratory failure between 1 and 2 years of age. The late onset form of the disease begins between childhood and adulthood and has a slower rate of progression that is characterized by musculoskeletal and pulmonary symptoms that usually lead to progressive weakness and respiratory insufficiency. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in AT2220 in the United States.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has two product candidates in Phase II clinical trials, Amigal(TM) for the treatment of Fabry
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
3. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
8. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... and NEW YORK , Aug. 1, ... Pershing Square Capital Management, L.P. today responded to the ... AGN ) in California.  The complaint makes ... tender offer rules.  Allergan,s true purpose ... with shareholders, efforts to call a special meeting.  That ...
(Date:8/1/2014)... 1, 2014  VanDeMark Chemical Inc., ... of phosgene and phosgene derivatives in ... has acquired Framochem Kft, a leading European-based manufacturer ... . The purchase unites two ... of the world,s largest, independent manufacturers of products ...
(Date:8/1/2014)... Aspire Technology Partners (Aspire) announced today that it has achieved ... recognizes Aspire for delivering outstanding customer service to customers in ... "Achieving exceptional results for our customers is core to ... CEO of Aspire. "We are pleased Cisco has recognized our ... are proud to be part of the Cisco channel." ...
Breaking Medicine Technology:Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 6VanDeMark Chemical Inc. Acquires Framochem 2VanDeMark Chemical Inc. Acquires Framochem 3VanDeMark Chemical Inc. Acquires Framochem 4Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2
(Date:8/1/2014)... Summer is here, and with it comes the ... and they can be a pain for dogs. Animal Emergency ... their customers get rid of ticks and prevent them completely. ... the summer, which is why they are so active during ... woodland areas and carry a number of diseases, including lyme ...
(Date:8/1/2014)... The American Telemedicine Association (ATA) ... and Peter Welch (D-VT), for their latest actions ... Act of 2014, which improves telemedicine coverage in ... improve healthcare access and affordability using telecommunications technology," ... "These cost-saving provisions are critical to improve telehealth ...
(Date:8/1/2014)... 01, 2014 The "Antimicrobial Coatings ... as Zinc Oxide, Titanium Dioxide, and Zinc Omadine), ... Construction, Food & Beverages, Textiles, and others), & ... Global Trends and Forecasts to 2018" analyzes the ... opportunities, and trends in the diverse geographical regions. ...
(Date:8/1/2014)... 2014 The North America Endpoint Security ... market in North America with analysis and forecast of ... $3.53 billion in 2014 to $4.77 billion by 2019, ... , Browse through the TOC of the North America ... the in-depth analysis provided. It also provides a glimpse ...
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 ... Generators Market Outlook to 2020", provides key ... Generators market. The report provides value, in ... and average prices (in US dollars) within ... Generators, Ultrasonic Generators and Argon Plasma Coagulation ...
Breaking Medicine News(10 mins):Health News:Tis the Season for Tick Prevention 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 2Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 3
... Julian, had a brain tumor the size of a golf ball. A ... diagnosed with the same rare form of cancer, called medulloblastoma. Before that, ... III Rhabdomyosarcoma, a very aggressive soft muscle tumor. , ... CHICAGO ...
... Nov. 6 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, Co., Inc., (Amex: ... traditional Chinese medicine ("TCM") based in Chengdu, China,today ... to discuss its,2009 fiscal first quarter at 8:30 ... will be released that day before the market ...
... N.J., Nov. 6 At RSNA 2008 ... MEDQ ) is introducing a,powerful integration ... speech recognition application, and RadWorkFlow(R), a,robust workflow ... offers an efficient, simplified, and consolidated view ...
... 6 Continuing its efforts to,educate, inform, and ... a,not-for-profit patient-focused organization, is hosting its 25-minute live,call-in ... on,Monday, November 10, 2008 at 6:00 PM on ... frank discussion with Joy Loverde, a,nationally known expert ...
... 6 Arizona-based Cain and Associates (C&A),( ... alliance with JDA eHealth Systems, Inc. of ... eHealth Systems will now be able to ... and GRIP (Government,Revenue Integrity Program) products to ...
... and CARLSBAD, Calif., Nov. 6, Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ),announces the following webcast:, ... late-stage research candidates, including presentations ... -- Dr. Erik Stroes reporting top line data from an ongoing ... liver imaging study -- Dr. ...
Cached Medicine News:Health News: Three Women in Health Crises Go Online to Form Lifelong Friendships : Mothers of Boys with Cancer Find Support, Encouragement and Each Other at CarePages.com 2Health News: Three Women in Health Crises Go Online to Form Lifelong Friendships : Mothers of Boys with Cancer Find Support, Encouragement and Each Other at CarePages.com 3Health News:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST 2Health News:MedQuist Introduces SpeechQ for Radiology Integrated with RadWorkFlow 2Health News:MedQuist Introduces SpeechQ for Radiology Integrated with RadWorkFlow 3Health News:Health Caring for the Elderly 2Health News:Cain & Associates Forms Strategic Partnership With JDA eHealth Systems, Inc. 2Health News:Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: